EsoBiotec
AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout
AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases
Actionable Insights Powered by AI
AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases